Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Next Previous
Trial Profile

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Mouth neoplasm; Squamous cell cancer; Tongue cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Mar 2024 Planned End Date changed from 1 Apr 2024 to 1 Dec 2024.
    • 11 Jul 2022 According to a TScan Therapeutics media release, the characterization of tumor-infiltrating and circulating T cells from this study published in the peer-reviewed article published in in the journal Cell.
    • 29 Feb 2020 Primary endpoint Volumetric response has been met as per results presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top